Japan Oncology Biosimilar Market Size & Outlook, 2026-2034

Japan Oncology Biosimilar Market Insights

Reed Intelligence analysis indicates that the Japan Oncology Biosimilar Market size, valued at USD 341.33 Million in 2025, is expected to expand to USD 1406.93 Million by 2034.
The Japan market is forecasted to expand at a CAGR of 17.08% spanning 2026–2034.
Monoclonal Antibodies (mAbs) held the leading position among By Product Type segments in 2025, based on market size.
Granulocyte Colony-Stimulating Factor (G-CSF) is projected to post the fastest growth rate, sustaining its position as the most attractive By Product Type segment during the forecast horizon.

Other Key Findings

In 2025, Japan accounted for 4.27% of the global Oncology Biosimilar Market size.
By 2034, United States is expected to lead the global Oncology Biosimilar Market in terms of market size.
Within Asia Pacific, China is projected to dominate the regional Oncology Biosimilar Market size by 2034.
Australia is identified as the fastest-growing market in Asia Pacific, anticipated to reach USD 727.91 Million by 2034.

Report Summary

Report Scope	Details
Base Year for Study	2025
Study Period	2022-2034
Historical Period	2022-2024
Forecast Period	2026-2034
Market Size In 2025	USD 341.33 Million
Market Size In 2034	USD 1406.93 Million
Largest segment	Monoclonal Antibodies (mAbs)
Units	Revenue in USD Million
CAGR	17.08% (2026-2034)
Segmnetation Covered
By Product Type	Monoclonal Antibodies (mAbs) Hematopoietic Agents Granulocyte Colony-Stimulating Factor (G-CSF) Immunomodulators
By Cancer Type	Breast Cancer Lung Cancer Colorectal Cancer Cervical Cancer Blood Cancer / Hematological Cancers Other types (e.g., kidney, stomach, brain cancers)
By Route of Administration	Intravenous (IV) Subcutaneous (SC) Others
By Distribution Channel	Hospital Pharmacies Retail Pharmacies Online Pharmacies Others
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Japan Oncology Biosimilar Market By Product Type 2026-2034 (USD Million)

By Product Type	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Monoclonal Antibodies (mAbs)	XX.x	XX.x	XX.x	158.31	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Hematopoietic Agents	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Granulocyte Colony-Stimulating Factor (G-CSF)	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Immunomodulators	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Japan Oncology Biosimilar Market By Cancer Type 2026-2034 (USD Million)

By Cancer Type	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Breast Cancer	XX.x	XX.x	XX.x	107.45	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Lung Cancer	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Colorectal Cancer	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Cervical Cancer	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Blood Cancer / Hematological Cancers	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Other types (e.g., kidney, stomach, brain cancers)	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Japan Oncology Biosimilar Market By Route of Administration 2026-2034 (USD Million)

By Route of Administration	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Intravenous (IV)	XX.x	XX.x	XX.x	156.16	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Subcutaneous (SC)	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Others	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Japan Oncology Biosimilar Market By Distribution Channel 2026-2034 (USD Million)

By Distribution Channel	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Hospital Pharmacies	XX.x	XX.x	XX.x	155.31	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Retail Pharmacies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Online Pharmacies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Others	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Author :

Reed Intelligence Research Team

The Reed Intelligence Research Team brings together over 15+ years of collective experience in market research, data analytics, and strategic consulting. Comprising seasoned analysts, economists, and industry specialists, the team delivers precise, data-driven insights across sectors including technology, healthcare, energy, manufacturing, and consumer goods. By combining domain expertise with modern analytical tools, they ensure each report meets the highest standards of accuracy and relevance.